Priyanka S. Mehta

Bristol, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 45 publications

CPX‑351 vs. FLAG‑ida in patients with high-risk AML/MDS and MDS-related gene mutations: a subgroup analysis of the UK NCRI AML19 trial.

CPX‑351 vs. FLAG‑ida in patients with high-risk AML/MDS and MDS-related gene mutations: a subgroup analysis of the UK NCRI AML19 trial.

Journal: Leukemia & lymphoma

Published: July 01, 2026

A Delphi Consensus on Optimising the Care Pathway for Adult Patients With Acute Myeloid Leukaemia (AML): Strategies to Enhance Transplant Accessibility and Feasibility in the United Kingdom.

A Delphi Consensus on Optimising the Care Pathway for Adult Patients With Acute Myeloid Leukaemia (AML): Strategies to Enhance Transplant Accessibility and Feasibility in the United Kingdom.

Journal: EJHaem

Published: March 30, 2026

Combining Quizartinib with intensive chemotherapy in older patients with newly diagnosed AML: results of the UK NCRI AML18 Trial.

Combining Quizartinib with intensive chemotherapy in older patients with newly diagnosed AML: results of the UK NCRI AML18 Trial.

Journal: Blood

Published: December 05, 2025

A Method for Enhancing Specialty Skills of Practicing Psychologists: Independent Learning Plan Experiences among Psychologists working in the Veterans Health Administration.

A Method for Enhancing Specialty Skills of Practicing Psychologists: Independent Learning Plan Experiences among Psychologists working in the Veterans Health Administration.

Journal: Professional psychology, research and practice

Published: September 02, 2025

CPX-351 vs daunorubicin, cytarabine, and gemtuzumab ozogamicin in older adults with non-adverse-risk AML: the NCRI AML18 trial.

CPX-351 vs daunorubicin, cytarabine, and gemtuzumab ozogamicin in older adults with non-adverse-risk AML: the NCRI AML18 trial.

Journal: Blood

Published: July 28, 2025

CPX-351 versus daunorubicin, cytarabine plus gemtuzumab ozogamicin in older adults with non-adverse risk AML: NCRI AML18.

CPX-351 versus daunorubicin, cytarabine plus gemtuzumab ozogamicin in older adults with non-adverse risk AML: NCRI AML18.

Journal: Blood

Published: July 28, 2025

Pesticide and Liver Biomarkers Among Ecuadorian Adolescents and Adults Living in Agricultural Settings.

Pesticide and Liver Biomarkers Among Ecuadorian Adolescents and Adults Living in Agricultural Settings.

Journal: Toxics

Published: June 07, 2025

Unmet needs in patients with acute myeloid leukemia ineligible for intensive approaches: perspectives from a European expert panel.

Unmet needs in patients with acute myeloid leukemia ineligible for intensive approaches: perspectives from a European expert panel.

Journal: Frontiers in oncology

Published: June 06, 2025

Venetoclax-based non-intensive combinations for relapsed/refractory acute myeloid leukaemia-Real-world data from a UK-wide programme.

Venetoclax-based non-intensive combinations for relapsed/refractory acute myeloid leukaemia-Real-world data from a UK-wide programme.

Journal: British journal of haematology

Published: January 21, 2025

Treatment Intensification With Either Fludarabine, AraC, G-CSF and Idarubicin, or Cladribine Plus Daunorubicin and AraC on the Basis of Residual Disease Status in Older Patients With AML: Results From the NCRI AML18 Trial.

Treatment Intensification With Either Fludarabine, AraC, G-CSF and Idarubicin, or Cladribine Plus Daunorubicin and AraC on the Basis of Residual Disease Status in Older Patients With AML: Results From the NCRI AML18 Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: November 18, 2024

Fitness assessment in acute myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.

Fitness assessment in acute myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.

Journal: Blood advances

Published: July 22, 2024

Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHS.

Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHS.

Journal: Blood neoplasia

Published: April 15, 2024

Showing 1-12 of 45

Last Updated: 09/26/2026